PUBLISHER: KBV Research | PRODUCT CODE: 1126589
PUBLISHER: KBV Research | PRODUCT CODE: 1126589
LAMEA Biosimilars Market Size, Share & Industry Trends Analysis Report By Application (Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others), By Type, By Country and Growth Forecast, 2022 - 2028
The Latin America, Middle East and Africa Biosimilars Market would witness market growth of 29.4% CAGR during the forecast period (2022-2028).
Biosimilars act as a supplemental form of chemotherapy and thus play a significant part in the treatment of cancer. Therefore, the prevalence of various cancers is rising will increase the demand for biosimilars. The FDA defines a biosimilar as a biological product that is extremely similar to and essentially identical to one that has already received FDA approval.
The reference product and the biosimilars share many structural as well as functional characteristics. Modern manufacturing techniques are used to create these products in order to compare properties such as bioactivity, purity, & chemical identity between the target product and reference product. Small variations in stabilizers or buffers, which are clinically inactive components, are acceptable.
This is clear biologics that have improved the way in which cancer, autoimmune diseases, and genetic conditions are treated, improving the futures of numerous people. No compromises are made in the product's safety, quality, or efficacy due to the FDA's standards for drug approval. This is true whether the treatment is a biologic or a biosimilar. Regardless of the method of treatment, both cutting-edge approaches signal exciting new directions in the management of complex diseases like cancer.
Being one of the Middle East's most developed and diverse economies, the UAE has a strong healthcare infrastructure. The UAE government has placed a high priority on developing a first-rate healthcare infrastructure, which has helped the sector expand and develop over the past few years. Given that public spending accounts for more than two-thirds of all healthcare expenditures, the UAE government's support for the medical sector is one of the main growth drivers in the country. The government's plans to improve national capabilities to fight upcoming pandemics include efforts to develop vaccines & medicines as well as a new supply chain-focused strategy.
The Brazil market dominated the LAMEA Biosimilars Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,076.7 million by 2028. The Argentina market is anticipated to grow at a CAGR of 30% during (2022 - 2028). Additionally, The UAE market would witness a CAGR of 29% during (2022 - 2028).
Based on Application, the market is segmented into Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Granulocyte-Colony Stimulating Factor, Erythropoietin, Human Growth Hormone, Insulin and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Biocon Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceutical Ltd, Novartis AG (Sandoz), Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and Fresenius SE & Co. KGaA
Scope of the Study
Market Segments covered in the Report:
By Application
- Oncology Diseases
- Blood Disorders
- Chronic & Autoimmune Diseases
- Others
By Type
- Monoclonal Antibodies
- Granulocyte-Colony Stimulating Factor
- Erythropoietin
- Human Growth Hormone
- Insulin
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Amgen, Inc.
- Biocon Limited
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Company
- Intas Pharmaceutical Ltd
- Novartis AG (Sandoz)
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Fresenius SE & Co. KGaA
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 LAMEA Biosimilars Market, by Application
- 1.4.2 LAMEA Biosimilars Market, by Type
- 1.4.3 LAMEA Biosimilars Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition & Scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
- 3.1 KBV Cardinal Matrix
- 3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Product Launches and Product Expansions
- 3.2.3 Acquisition and Mergers
- 3.2.4 Approvals and Trials
- 3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
- 3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jun - 2022, Aug) Leading Players
Chapter 4. LAMEA Biosimilars Market by Application
- 4.1 LAMEA Oncology Diseases Market by Country
- 4.2 LAMEA Blood Disorders Market by Country
- 4.3 LAMEA Chronic & Autoimmune Diseases Market by Country
- 4.4 LAMEA Others Market by Country
Chapter 5. LAMEA Biosimilars Market by Type
- 5.1 LAMEA Monoclonal Antibodies Market by Country
- 5.2 LAMEA Granulocyte-Colony Stimulating Factor Market by Country
- 5.3 LAMEA Erythropoietin Market by Country
- 5.4 LAMEA Human Growth Hormone Market by Country
- 5.5 LAMEA Insulin Market by Country
- 5.6 LAMEA Others Market by Country
Chapter 6. LAMEA Biosimilars Market by Country
- 6.1 Brazil Biosimilars Market
- 6.1.1 Brazil Biosimilars Market by Application
- 6.1.2 Brazil Biosimilars Market by Type
- 6.2 Argentina Biosimilars Market
- 6.2.1 Argentina Biosimilars Market by Application
- 6.2.2 Argentina Biosimilars Market by Type
- 6.3 UAE Biosimilars Market
- 6.3.1 UAE Biosimilars Market by Application
- 6.3.2 UAE Biosimilars Market by Type
- 6.4 Saudi Arabia Biosimilars Market
- 6.4.1 Saudi Arabia Biosimilars Market by Application
- 6.4.2 Saudi Arabia Biosimilars Market by Type
- 6.5 South Africa Biosimilars Market
- 6.5.1 South Africa Biosimilars Market by Application
- 6.5.2 South Africa Biosimilars Market by Type
- 6.6 Nigeria Biosimilars Market
- 6.6.1 Nigeria Biosimilars Market by Application
- 6.6.2 Nigeria Biosimilars Market by Type
- 6.7 Rest of LAMEA Biosimilars Market
- 6.7.1 Rest of LAMEA Biosimilars Market by Application
- 6.7.2 Rest of LAMEA Biosimilars Market by Type
Chapter 7. Company Profiles
- 7.1 Fresenius SE & Co. KGaA
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental and Regional Analysis
- 7.1.4 Research & Development Expenses
- 7.1.5 Recent strategies and developments:
- 7.1.5.1 Approvals and Trials:
- 7.1.5.2 Product Launches and Product Expansions:
- 7.1.5.3 Acquisition and Mergers:
- 7.2 Dr. Reddy's Laboratories Ltd.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Segmental and Regional Analysis
- 7.2.4 Research & Development Expense
- 7.2.5 Recent strategies and developments:
- 7.2.5.1 Partnerships, Collaborations, and Agreements:
- 7.2.5.2 Product Launches and Product Expansions:
- 7.3 Pfizer, Inc.
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Regional & Segmental Analysis
- 7.3.4 Research & Development Expense
- 7.3.5 Recent strategies and developments:
- 7.3.5.1 Approvals and Trials:
- 7.3.5.2 Product Launches and Product Expansions:
- 7.3.5.3 Acquisition and Mergers:
- 7.4 Amgen, Inc.
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Regional Analysis
- 7.4.4 Research & Development Expenses
- 7.4.5 Recent strategies and developments:
- 7.4.5.1 Approvals and Trials:
- 7.4.5.2 Product Launches and Product Expansions:
- 7.4.5.3 Acquisition and Mergers:
- 7.5 Teva Pharmaceutical Industries Ltd.
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Regional Analysis
- 7.5.4 Research & Development Expenses
- 7.5.5 Recent strategies and developments:
- 7.5.5.1 Partnerships, Collaborations, and Agreements:
- 7.5.5.2 Approvals and Trials:
- 7.5.5.3 Product Launches and Product Expansions:
- 7.6 Eli Lilly And Company
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Regional Analysis
- 7.6.4 Research & Development Expenses
- 7.6.5 Recent strategies and developments:
- 7.6.5.1 Partnerships, Collaborations, and Agreements:
- 7.7 Merck & Co., Inc.
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Segmental and Regional Analysis
- 7.7.4 Research & Development Expenses
- 7.7.5 Recent strategies and developments:
- 7.7.5.1 Product Launches and Product Expansions:
- 7.8 Novartis AG (Sandoz)
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
- 7.8.5 Recent strategies and developments:
- 7.8.5.1 Partnerships, Collaborations, and Agreements:
- 7.8.5.2 Approvals and Trials:
- 7.9 Biocon Limited
- 7.9.1 Company Overview
- 7.9.2 Recent strategies and developments:
- 7.9.2.1 Partnerships, Collaborations, and Agreements:
- 7.9.2.2 Product Launches and Product Expansions:
- 7.9.2.3 Acquisition and Mergers:
- 7.10. Intas Pharmaceutical Ltd.
- 7.10.1 Company Overview
- 7.10.2 Recent strategies and developments:
- 7.10.2.1 Partnerships, Collaborations, and Agreements:
- 7.10.2.2 Product Launches and Product Expansions:
LIST OF TABLES
- TABLE 1 LAMEA Biosimilars Market, 2018 - 2021, USD Million
- TABLE 2 LAMEA Biosimilars Market, 2022 - 2028, USD Million
- TABLE 3 Partnerships, Collaborations and Agreements- Biosimilars Market
- TABLE 4 Product Launches And Product Expansions- Biosimilars Market
- TABLE 5 Acquisition and Mergers- Biosimilars Market
- TABLE 6 Approvals and Trials - Biosimilars Market
- TABLE 7 LAMEA Biosimilars Market by Application, 2018 - 2021, USD Million
- TABLE 8 LAMEA Biosimilars Market by Application, 2022 - 2028, USD Million
- TABLE 9 LAMEA Oncology Diseases Market by Country, 2018 - 2021, USD Million
- TABLE 10 LAMEA Oncology Diseases Market by Country, 2022 - 2028, USD Million
- TABLE 11 LAMEA Blood Disorders Market by Country, 2018 - 2021, USD Million
- TABLE 12 LAMEA Blood Disorders Market by Country, 2022 - 2028, USD Million
- TABLE 13 LAMEA Chronic & Autoimmune Diseases Market by Country, 2018 - 2021, USD Million
- TABLE 14 LAMEA Chronic & Autoimmune Diseases Market by Country, 2022 - 2028, USD Million
- TABLE 15 LAMEA Others Market by Country, 2018 - 2021, USD Million
- TABLE 16 LAMEA Others Market by Country, 2022 - 2028, USD Million
- TABLE 17 LAMEA Biosimilars Market by Type, 2018 - 2021, USD Million
- TABLE 18 LAMEA Biosimilars Market by Type, 2022 - 2028, USD Million
- TABLE 19 LAMEA Monoclonal Antibodies Market by Country, 2018 - 2021, USD Million
- TABLE 20 LAMEA Monoclonal Antibodies Market by Country, 2022 - 2028, USD Million
- TABLE 21 LAMEA Granulocyte-Colony Stimulating Factor Market by Country, 2018 - 2021, USD Million
- TABLE 22 LAMEA Granulocyte-Colony Stimulating Factor Market by Country, 2022 - 2028, USD Million
- TABLE 23 LAMEA Erythropoietin Market by Country, 2018 - 2021, USD Million
- TABLE 24 LAMEA Erythropoietin Market by Country, 2022 - 2028, USD Million
- TABLE 25 LAMEA Human Growth Hormone Market by Country, 2018 - 2021, USD Million
- TABLE 26 LAMEA Human Growth Hormone Market by Country, 2022 - 2028, USD Million
- TABLE 27 LAMEA Insulin Market by Country, 2018 - 2021, USD Million
- TABLE 28 LAMEA Insulin Market by Country, 2022 - 2028, USD Million
- TABLE 29 LAMEA Others Market by Country, 2018 - 2021, USD Million
- TABLE 30 LAMEA Others Market by Country, 2022 - 2028, USD Million
- TABLE 31 LAMEA Biosimilars Market by Country, 2018 - 2021, USD Million
- TABLE 32 LAMEA Biosimilars Market by Country, 2022 - 2028, USD Million
- TABLE 33 Brazil Biosimilars Market, 2018 - 2021, USD Million
- TABLE 34 Brazil Biosimilars Market, 2022 - 2028, USD Million
- TABLE 35 Brazil Biosimilars Market by Application, 2018 - 2021, USD Million
- TABLE 36 Brazil Biosimilars Market by Application, 2022 - 2028, USD Million
- TABLE 37 Brazil Biosimilars Market by Type, 2018 - 2021, USD Million
- TABLE 38 Brazil Biosimilars Market by Type, 2022 - 2028, USD Million
- TABLE 39 Argentina Biosimilars Market, 2018 - 2021, USD Million
- TABLE 40 Argentina Biosimilars Market, 2022 - 2028, USD Million
- TABLE 41 Argentina Biosimilars Market by Application, 2018 - 2021, USD Million
- TABLE 42 Argentina Biosimilars Market by Application, 2022 - 2028, USD Million
- TABLE 43 Argentina Biosimilars Market by Type, 2018 - 2021, USD Million
- TABLE 44 Argentina Biosimilars Market by Type, 2022 - 2028, USD Million
- TABLE 45 UAE Biosimilars Market, 2018 - 2021, USD Million
- TABLE 46 UAE Biosimilars Market, 2022 - 2028, USD Million
- TABLE 47 UAE Biosimilars Market by Application, 2018 - 2021, USD Million
- TABLE 48 UAE Biosimilars Market by Application, 2022 - 2028, USD Million
- TABLE 49 UAE Biosimilars Market by Type, 2018 - 2021, USD Million
- TABLE 50 UAE Biosimilars Market by Type, 2022 - 2028, USD Million
- TABLE 51 Saudi Arabia Biosimilars Market, 2018 - 2021, USD Million
- TABLE 52 Saudi Arabia Biosimilars Market, 2022 - 2028, USD Million
- TABLE 53 Saudi Arabia Biosimilars Market by Application, 2018 - 2021, USD Million
- TABLE 54 Saudi Arabia Biosimilars Market by Application, 2022 - 2028, USD Million
- TABLE 55 Saudi Arabia Biosimilars Market by Type, 2018 - 2021, USD Million
- TABLE 56 Saudi Arabia Biosimilars Market by Type, 2022 - 2028, USD Million
- TABLE 57 South Africa Biosimilars Market, 2018 - 2021, USD Million
- TABLE 58 South Africa Biosimilars Market, 2022 - 2028, USD Million
- TABLE 59 South Africa Biosimilars Market by Application, 2018 - 2021, USD Million
- TABLE 60 South Africa Biosimilars Market by Application, 2022 - 2028, USD Million
- TABLE 61 South Africa Biosimilars Market by Type, 2018 - 2021, USD Million
- TABLE 62 South Africa Biosimilars Market by Type, 2022 - 2028, USD Million
- TABLE 63 Nigeria Biosimilars Market, 2018 - 2021, USD Million
- TABLE 64 Nigeria Biosimilars Market, 2022 - 2028, USD Million
- TABLE 65 Nigeria Biosimilars Market by Application, 2018 - 2021, USD Million
- TABLE 66 Nigeria Biosimilars Market by Application, 2022 - 2028, USD Million
- TABLE 67 Nigeria Biosimilars Market by Type, 2018 - 2021, USD Million
- TABLE 68 Nigeria Biosimilars Market by Type, 2022 - 2028, USD Million
- TABLE 69 Rest of LAMEA Biosimilars Market, 2018 - 2021, USD Million
- TABLE 70 Rest of LAMEA Biosimilars Market, 2022 - 2028, USD Million
- TABLE 71 Rest of LAMEA Biosimilars Market by Application, 2018 - 2021, USD Million
- TABLE 72 Rest of LAMEA Biosimilars Market by Application, 2022 - 2028, USD Million
- TABLE 73 Rest of LAMEA Biosimilars Market by Type, 2018 - 2021, USD Million
- TABLE 74 Rest of LAMEA Biosimilars Market by Type, 2022 - 2028, USD Million
- TABLE 75 key information - Fresenius SE & Co. KGaA
- TABLE 76 key information - Dr. Reddy's Laboratories Ltd.
- TABLE 77 Key Information - Pfizer, Inc.
- TABLE 78 Key Information - Amgen, Inc.
- TABLE 79 Key Information - Teva Pharmaceuticals Industries Ltd.
- TABLE 80 Key Information - Eli Lilly And Company
- TABLE 81 KEY INFORMATION - MERCK & CO., INC.
- TABLE 82 Key Information - Novartis AG
- TABLE 83 Key Information - Biocon Limited
- TABLE 84 Key Information - Intas Pharmaceutical Ltd.
List of Figures
- FIG 1 Methodology for the research
- FIG 2 KBV Cardinal Matrix
- FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
- FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jan - 2022, Aug) Leading Players
- FIG 5 Recent strategies and developments: Fresenius SE & Co. KGaA
- FIG 6 Recent strategies and developments: Dr. Reddy's Laboratories Ltd.
- FIG 7 Recent strategies and developments: Pfizer, Inc.
- FIG 8 Recent strategies and developments: Amgen, Inc.
- FIG 9 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
- FIG 10 Recent strategies and developments: Novartis AG
- FIG 11 Recent strategies and developments: Biocon Limited
- FIG 12 Recent strategies and developments: Intas Pharmaceutical Ltd.
